NASDAQ:BOLD - Audentes Therapeutics Stock Price, Forecast & News

Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."

Audentes Therapeutics Inc (NASDAQ:BOLD) issued its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($1.07) by $0.07. During the same quarter last year, the company posted ($0.97) EPS. View Audentes Therapeutics' Earnings History.

16 Wall Street analysts have issued twelve-month target prices for Audentes Therapeutics' shares. Their forecasts range from $10.00 to $60.00. On average, they expect Audentes Therapeutics' stock price to reach $50.54 in the next year. This suggests that the stock has a possible downside of 15.7%. View Analyst Price Targets for Audentes Therapeutics.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Audentes Therapeutics in the last year. There are currently 14 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Audentes Therapeutics.

Media headlines about BOLD stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Audentes Therapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Audentes Therapeutics.

Some companies that are related to Audentes Therapeutics include Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), Acceleron Pharma (XLRN), China Biologic Products (CBPO), Repligen (RGEN), Spark Therapeutics (ONCE), bluebird bio (BLUE), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT) and Momenta Pharmaceuticals (MNTA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Audentes Therapeutics investors own include Energy Transfer LP Unit (ET), Crispr Therapeutics (CRSP), Clovis Oncology (CLVS), Exelixis (EXEL), Global Blood Therapeutics (GBT), Gilead Sciences (GILD), Intel (INTC), Ionis Pharmaceuticals (IONS), Myriad Genetics (MYGN) and bluebird bio (BLUE).

(BOLD) raised $75 million in an initial public offering (IPO) on Wednesday, July 20th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Audentes Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Magnetar Financial LLC (3.45%), CNH Partners LLC (2.94%), State Street Corp (2.83%), Partner Fund Management L.P. (2.66%), Farallon Capital Management LLC (2.57%) and RA Capital Management L.P. (1.95%). Company insiders that own Audentes Therapeutics stock include David Nagler, John T Gray, Louis G Lange, Mary Newman, Matthew R Patterson, Orbimed Advisors Llc and Suyash Prasad. View Institutional Ownership Trends for Audentes Therapeutics.

BOLD stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Partner Fund Management L.P., Jennison Associates LLC, State Street Corp, UBS Asset Management Americas Inc., Candriam Luxembourg S.C.A., Spark Investment Management LLC and Rafferty Asset Management LLC. Company insiders that have sold Audentes Therapeutics company stock in the last year include Louis G Lange, Matthew R Patterson and Suyash Prasad. View Insider Buying and Selling for Audentes Therapeutics.

BOLD stock was purchased by a variety of institutional investors in the last quarter, including Magnetar Financial LLC, CNH Partners LLC, Farallon Capital Management LLC, RA Capital Management L.P., Bank of America Corp DE, Syquant Capital Sas, Gabelli Funds LLC and ARP Americas LP. View Insider Buying and Selling for Audentes Therapeutics.

Shares of BOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BOLD stock can currently be purchased for approximately $59.97.

Audentes Therapeutics has a market capitalization of $2.77 billion. The biotechnology company earns $-128,820,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Audentes Therapeutics employs 207 workers across the globe.View Additional Information About Audentes Therapeutics.

The official website for Audentes Therapeutics is http://www.audentestx.com/.

Audentes Therapeutics' mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company can be reached via phone at 415-818-1001 or via email at [email protected]